Terms: = Breast cancer AND FBXW7, AGO, 55294, ENSG00000109670, FLJ11071, SEL-10, CDC4, FBXW6, SEL10, FBW7, DKFZp686F23254, FBX30 AND Clinical Outcome
5 results:
1. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized ago-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
2. FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene fbxw7.
Wang Z; Liu Y; Zhang P; Zhang W; Wang W; Curr K; Wei G; Mao JH
Oncotarget; 2013 Dec; 4(12):2476-86. PubMed ID: 24344117
[TBL] [Abstract] [Full Text] [Related]
3. Trimodal therapy for inflammatory breast cancer: a surgeon's perspective.
Li BD; Sicard MA; Ampil F; Abreo F; Lilien D; Chu QD; Burton GV
Oncology; 2010; 79(1-2):3-12. PubMed ID: 21051912
[TBL] [Abstract] [Full Text] [Related]
4. A vision to optimise the management of primary breast cancer in older women.
Cheung KL; Morgan DA; Winterbottom L; Richardson H; Ellis IO; Porock D
Breast; 2010 Apr; 19(2):153-5. PubMed ID: 20172727
[TBL] [Abstract] [Full Text] [Related]
5. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Annecke K; Schmitt M; Euler U; Zerm M; Paepke D; Paepke S; von Minckwitz G; Thomssen C; Harbeck N
Adv Clin Chem; 2008; 45():31-45. PubMed ID: 18429492
[TBL] [Abstract] [Full Text] [Related]
